LONDON and RALEIGH, NC, August 29, 2022 (GLOBE NEWSWIRE) — Verona Pharma plc VRNA (“Verona Pharma” or the “Company”), announces that management will present a company overview at HC Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 p.m. ET / 7:00 p.m. BST.
A webcast of the event will be available through the Events and Presentations link on the Investors page of the Company’s website. www.veronapharma.com.
For more information please contact:
| Verona Pharma plc | US Phone: +1-833-417-0262 UK Tel: +44 (0)203 283 4200 |
| Victoria Stewart, Director of Investor Relations and Communications | info@veronapharma.com |
| Argot partner (requests from US investors) |
Tel: +1-212-600-1902 verona@argotpartners.com |
| Kimberly Minarovich / Carrie McKim | |
| Optimal strategic communication (International media and European investor inquiries) |
Tel: +44 (0)203 950 9144 verona@optimumcomms.com |
| Mary Clark / Rebecca Noonan / Zoe Bolt |
About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrin, has the potential to become the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory effects in one compound. The Company is evaluating nebulized ensifentrin in its Phase 3 clinical program ENHANCE (Ensifentrin as Novel inHAled Nebulized COPD Therapy) for maintenance treatment of COPD. Ensifentrin met the primary endpoint in ENHANCE-2, demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrin significantly reduced the rate of COPD exacerbations in the ENHANCE-2 study. Two additional ensifentrin formulations are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized…
[ad_2]
Source story
